A roadmap for the generation of benchmarking resources for antimicrobial resistance detection using next generation sequencing [version 2; peer review: 2 approved with reservations]

Mauro Petrillo¹¹*, Marco Fabbri¹¹*, Dafni Maria Kagkli¹¹*, Maddalena Querci¹¹, Guy Van den Eede¹², Erik Alm³, Derya Aytan-Aktug⁴, Salvador Capella-Gutierrez⁵, Catherine Carrillo⁶, Alessandro Cestaro⁷, Kok-Gan Chan⁸,⁹, Teresa Coque¹⁰,¹¹, Christoph Endrullat¹², Ivo Gut¹³,¹⁴, Paul Hammer¹⁵, Gemma L. Kay¹⁶, Jean-Yves Madec¹⁷, Alison E. Mather¹⁶,¹⁸, Alice Carolyn McHardy¹⁹, Thierry Naas²⁰, Valentina Paracchini¹, Silke Peter²¹, Arthur Pightling²², Barbara Raffael¹, John Rossen²³, Etienne Ruppé²⁴, Robert Schlaberg²⁵, Kevin Vanneste²⁶, Lukas M. Weber²⁷,²⁸,²⁹, Henrik Westh³⁰, Alexandre Angers-Loustau³¹*
Abstract
Next Generation Sequencing technologies significantly impact the field of Antimicrobial Resistance (AMR) detection and monitoring, with immediate uses in diagnosis and risk assessment. For this application and in general, considerable challenges remain in demonstrating sufficient trust to act upon the meaningful information produced from raw data, partly because of the reliance on bioinformatics pipelines, which can produce different results and therefore lead to different interpretations. With the constant evolution of the field, it is difficult to identify, harmonise and recommend specific methods for large-scale implementations over time. In this article, we propose to address this challenge through establishing a transparent, performance-based, evaluation approach to provide flexibility in the bioinformatics tools of choice, while demonstrating proficiency in meeting common performance standards. The approach is two-fold: first, a community-driven effort to establish and maintain “live” (dynamic) benchmarking platforms to provide relevant performance metrics, based on different use-cases, that would evolve together with the AMR field; second, agreed and defined datasets to allow the pipelines’ implementation, validation, and quality-control over time. Following previous discussions on the main challenges linked to this approach, we provide concrete recommendations and future steps, related to different aspects of the design of benchmarks, such as the selection and the characteristics of the datasets (quality, choice of pathogens and resistances, etc.), the evaluation criteria of the pipelines, and the way these resources should be deployed in the community.

Keywords
Antimicrobial resistance, bioinformatics, next-generation sequencing, benchmarking
Corresponding authors: Mauro Petrillo (mauro.petrillo@ext.ec.europa.eu), Marco Fabbri (Marco.FABBRI@ec.europa.eu)

Author roles: Petrillo M: Conceptualization, Methodology, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Fabbri M: Conceptualization, Methodology, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; Kagkli DM: Conceptualization, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; Querci M: Conceptualization, Funding Acquisition, Methodology, Project Administration, Supervision, Writing – Review & Editing; Van den Eede G: Conceptualization, Funding Acquisition, Project Administration, Supervision, Writing – Review & Editing; Alm E: Conceptualization, Methodology, Writing – Review & Editing; Aytan-Aktug D: Conceptualization, Methodology, Writing – Review & Editing; Capella-Gutierrez S: Conceptualization, Methodology, Writing – Review & Editing; Carrillo C: Conceptualization, Methodology, Writing – Review & Editing; Coque T: Conceptualization, Methodology, Writing – Review & Editing; Gut I: Conceptualization, Methodology, Writing – Review & Editing; Hammer P: Conceptualization, Methodology, Writing – Review & Editing; Mather AE: Conceptualization, Methodology, Writing – Review & Editing; McHardy AC: Conceptualization, Methodology, Writing – Review & Editing; Naas T: Conceptualization, Methodology, Writing – Review & Editing; Paracchini V: Conceptualization, Methodology, Writing – Review & Editing; Peter S: Conceptualization, Methodology, Writing – Review & Editing; Pightling A: Conceptualization, Methodology, Writing – Review & Editing; Raffael B: Conceptualization, Methodology, Writing – Review & Editing; Rossen J: Conceptualization, Methodology, Writing – Review & Editing; Ruppé E: Conceptualization, Methodology, Writing – Review & Editing; Schlaberg R: Conceptualization, Methodology, Writing – Review & Editing; Vanneste K: Conceptualization, Methodology, Writing – Review & Editing; Weber LM: Conceptualization, Methodology, Writing – Review & Editing; Westh H: Conceptualization, Methodology, Writing – Review & Editing; Angers-Loustau A: Conceptualization, Methodology, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The "Benchmarking of NGS bioinformatics pipelines for AMR" meeting (27-28 of May 2019) was funded by the European Commission’s Joint Research Centre (JRC), Ispra, Italy. AEM is supported by the Biotechnology and Biological Sciences Research Council Institute Strategic Programme Grant Microbes in the Food Chain BB/R012504/1 and its constituent project BB/S/E/F/000PR10348 (Theme 1, Epidemiology and Evolution of Pathogens in the Food Chain).

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2022 Petrillo M et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Petrillo M, Fabbri M, Kagkli DM et al. A roadmap for the generation of benchmarking resources for antimicrobial resistance detection using next generation sequencing [version 2; peer review: 2 approved with reservations] F1000Research 2022, 10:80 https://doi.org/10.12688/f1000research.39214.2

First published: 08 Feb 2021, 10:80 https://doi.org/10.12688/f1000research.39214.1
1. Introduction

The technological advances in Whole Genome Sequencing (WGS) and the increasing integration of Next Generation Sequencing (NGS) platforms in the arsenal of testing laboratories is having a profound impact on health sciences. Affordable human genome sequencing is bringing about an era of improved diagnostics and personalised healthcare. For microorganisms, the reliable characterisation of their genetic material allows improved insights in their identity and physiology. For example, once sequenced, the genome of a microorganism can also be used to (re-)identify the species and infer important phenotypic properties, such as virulence, resistance to antibiotics, typing and other adaptive traits. In addition, novel strategies for the implementation and analysis of NGS data are being developed and improved, and they can be used, for instance, to reconstruct the timeline and relationships between the cases of an infectious disease outbreak, which is something difficult to achieve with classical microbiological techniques.

An important aspect of the implementation of NGS technologies are considerations related to quality and consistency (see 1), in particular if the result of the method is to be used in a regulatory context (for example, in a monitoring framework) or, more importantly, in a clinical setting linked to decisions on medical treatments2-4, veterinary, agricultural or environmental interventions and food safety5,6 which may be linked under One Health initiatives.

Methods for predicting antimicrobial resistance (AMR) based on genetic determinants from NGS data rely on complex bioinformatics algorithms and procedures to transform the large output produced by the sequencing technologies into relevant information. Traditionally, regulatory implementation of analytical methods focuses on harmonisation of the protocol and the subsequent steps of analysis, i.e. ensuring the implementation of specific methods previously validated according to a set of criteria. For methods with important bioinformatics components, this is often not optimal, due to both the large variability in the developed strategies, variations in the particular computational resources available and the speed at which technologies and analytical approaches evolve. For the prediction of AMR determinants, very different strategies have been proposed, processing the sequencing data either as a set of reads or as pre-processed assemblies7-8, even using neural networks9; sometimes, the system itself is proprietary and operates as a “black box” from the point of view of the user. In such cases like this, it has been proposed to approach the quality assurance challenge through performance-based evaluations, i.e. ensuring that the implemented methods, although different, perform at a similar (acceptable) level in this context10. The same performance-based evaluation can then be applied whenever a component of the pipeline, or its environment, is replaced or updated.

An important component for a performance-based evaluation scheme is the availability of resources (in particular, datasets) that enable these evaluations11-13. In 2017, the Joint Research Centre (JRC) initiated a reflection on the subject by inviting experts in the field of AMR detection with NGS from the four compartments of a “One Health” perspective, i.e. clinics, food, animals and the environment14,15. These discussions led to a compilation of the challenges involved in the development of a benchmark strategy for bioinformatics pipelines, both for NGS-based approaches in general and in this specific field of application16. These challenges were grouped into often overlapping categories, including the nature of the samples in the dataset (e.g. their origin, quality and associated metadata), their composition (e.g. the determinants and species to include), their use (e.g. expected results and performance thresholds) and their sustainability (e.g. their development, release and update).

On the 27th and 28th of May 2019, the JRC held a follow-up meeting, including most of the authors of the original article and additional experts that expressed interest, to discuss and propose solutions to the identified challenges for AMR detection using next generation sequencing. The present article represents a summary of these discussions and the conclusions reached. We propose this document as a baseline for a roadmap and guidelines to harmonise and standardise for the generation of the benchmark resources in the field of AMR.

2. Framing the aims and purposes of the benchmarking resources

An important observation that arose from the two-day discussions is that the concept of benchmarking, even when focusing on a single component of the method (i.e. the bioinformatics pipeline), may refer to different activities that can vary in their scope and objectives (see also 17-19). Clarifying these scopes is crucial when proposing recommendations, as these (and the final datasets) will be influenced by the scope of the evaluation.

In the conclusions of Angers et al. article, the use of the benchmark resources was reported as follows: “(1) Ensuring confidence in the implementation of the bioinformatics component of the procedure, a step currently identified as limiting in the field. (2) Allowing evaluation and comparison of new/existing bioinformatics strategies, resources and tools. (3) Contributing to the validation of specific pipelines and the proficiency testing of testing laboratories and (4) “Future-proofing” bioinformatics pipelines to updates and replacement of tools and resources used in their different steps”14.

These four summarising points made above, in practice, cover two different questions: 1, 3 and 4 (implementation, validation,
proficiency testing and future proofing) ask whether the bioinformatics pipeline performs as expected, while 2 (evaluation/comparison) focuses on identifying gold standard pipelines and resources for implementation. The first scope of a benchmark resource would thus address the question: “Which pipeline performs best and at least by the agreed minimum standards?” A second scope addresses the question: “What is the quality of the information produced by the implemented bioinformatics pipeline?”

The latter question requires further refinement, based on the “what” the pipeline is “required” to achieve. Although there may be different contexts to the use of the methods (e.g. guide clinical intervention, contribute data to a monitoring framework, outbreak management, monitor the spread of AMR genes (ARGs) in or between different settings/environments, etc.), for a benchmark resource, these can be split in three main use cases:

- to predict the resistance of a pathogen of interest based on the identification of ARGs (either acquired ARGs and/or chromosomal point mutations conferring AMR);
- to identify the link of ARGs to a specific taxon in a metagenomic sample (i.e. taxon-binning approaches like described by Sangwan et al.);
- to identify the complete repertoire of the AMR determinants (i.e. the resistome) in a complex bacterial community from which total genomic DNA has been extracted and sequenced (i.e. the metagenome).

Finally, another important scope for a benchmark resource was identified, having, once again, an impact on the decisions regarding the benchmark dataset: “How robust is the bioinformatics pipeline?” Studies addressing this question focus on identifying how the pipelines can tolerate variation in characteristics of the input data, most often related to the quality of the sample or sequencing steps: robustness against contamination or low number/poor quality reads, for example. Robustness, in certain contexts, could also be seen as the effect (or lack of) of swapping a tool (or the reference database) at a certain step in the pipeline for a different one that is functionally equivalent (see, for example,).

In summary, it is important to be specific about the purpose and scope of the benchmark resource in the decisions taken when generating the datasets. We propose that the scope of a benchmark has three major parts, summarised in Figure 1.

### General considerations

When discussing the different challenges described in rarely can an absolute “best” answer be identified for a given question; recommendations thus need to be made, taking into account the specific purpose of the benchmark resource and the fact that they may evolve with the state-of-the-art in the field.

Still, some general observations and conclusions were proposed regarding difficulties like what type of AMR mechanisms to include, which pathogens to consider, lack of expertise and of harmonisation, rapid evolution of the fields of informatics and bioinformatics in parallel to progress of scientific knowledge on AMR. They are summarised in this section and, by discussing two main use cases for benchmarking resources (single isolates and mixed samples), represent proposals for a way through these and other challenges with common, transparent, performance-based evaluation approaches, to be applied in different fields in a “One Health” perspective.

### Scope of benchmark

<table>
<thead>
<tr>
<th>Scope</th>
<th>Uses</th>
</tr>
</thead>
</table>
| 1. Is the bioinformatics pipeline performing according to (agreed) minimum standards? | • Validation  
• Verification of implementation  
• QC over time and updates |
| 2. What is the quality of the information produced by the bioinformatics pipeline? | • Compare different pipelines/strategies/components  
• Identify “gold standards” for given applications |
| a. Prediction of AM resistance/susceptibility | • Test the effects of “noise” or other variations of input data characteristics. |
| b. Characterisation of resistome |

**Figure 1.** Summary of the different “scopes” for the benchmark resources for AMR detection using next generation sequencing discussed in the current document, with an indication of the uses for each.
2.1. NGS platforms

A quick analysis of the different NGS platforms currently available and in development makes it obvious that the set of reads that they produce have very different characteristics. In addition, each platform has its strengths and weaknesses. Both the error rate (about 0.1% for Illumina (RRID:SCR_010233), 1–10% for newer technologies like from Pacific Biosciences and Oxford Nanopore Technologies (RRID:SCR_003756)) and the types of errors (miscalls, insertions or deletions, or problems of particular motifs such as homopolymer sequences) vary according to the platform used. The average length of the reads can vary from hundreds (Illumina, Ion Torrent) to thousands (PacBio, Nanopore) of base pairs\textsuperscript{22–24}.

Bioinformatics pipelines are thus usually designed to handle the output of a specific platform, often in a certain configuration. Although exceptions exist (e.g. \textsuperscript{25,26}), in the context of a benchmark resource (and independently of the question asked), we thus believe that different datasets are needed for each of the different NGS platforms, each containing reads that have a profile that matches closely with the normal output of the respective technologies. It is important, in this case, to ensure that the datasets produced for the different platforms are developed so that they do not inadvertently introduce any bias resulting in apparent difference in performance among the different platforms due to composition of the benchmark dataset (e.g. when bioinformatics pipelines analysing the output of different platforms are compared). Although the absence of bias may be hard to demonstrate \textit{a posteriori}, efforts should be made to ensure that the datasets derive from strategies that are as similar as possible, for example by containing reads generated from the same input samples.

The platforms for which benchmark datasets are produced should be selected based on pragmatic considerations. Ideally, equivalent resources should be available for all technologies; however, it may be necessary to prioritize the most common platforms if resource limitations are an issue. Recent surveys have shown a clear preference for the Illumina platform in this context\textsuperscript{27,28}. The same trend can be observed when counting the number of published articles in a scientific literature database (Figure 2). That being said, sequencing technologies are constantly evolving, and benchmark datasets should be extended to new technologies with improved performance as these are increasingly adopted by testing laboratories.

The so-called “Third Generation Sequencing” technologies that sequence single DNA molecules and, importantly, produce long reads, have been shown to provide substantial benefits in the context of AMR detection. First, many resistance genes are located on plasmids, which are challenging to assemble using short-read sequencing technologies, because the short read lengths do not allow spanning of repetitive regions\textsuperscript{29}. The presence of an AMR determinant on a plasmid is also important for its transfer and eventual spread, and thus their correct assembly using long-read technologies represent a substantial advantage\textsuperscript{30–34}. In addition, the proper and timely treatment of a pathogen infection is critical for successful prevention and control of diseases in clinical settings as well as in the community. In line with this, the Nanopore sequencing technology has shown the promise of providing accurate antibiotic resistance gene identification within six hours of sample acquisition\textsuperscript{35–37}. We thus propose to include DNA Nanopore sequencing as an additional priority platform to develop benchmark resources.

The choice of formats for the different components of the datasets is also important. Each instrument produces a raw data output in a specific format (for example, the Illumina platforms generate raw data files in binary base call (BCL) format,

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{figure2.png}
\caption{Number of articles published each year in the scientific literature mentioning the selected platform. Source: Scopus, using the search: ALL (“X” AND “antimicrobial resistance”).}
\end{figure}
while the Nanopore platforms produce FAST5 (HDF5) files). However, the entry point of most bioinformatics pipelines in this context is the description of the sequence of the produced reads, with an indication of the quality (or confidence) score for each of the base positions. The FASTQ format is a standard format in this context\textsuperscript{38}, which should be used in the benchmark resources; many tools exist to convert the raw data output files into this format in case of different platform outputs (see, for example,\textsuperscript{39,40}) although, it should be noted, different tools may produce different results and this step should be carefully planned.

Other standard formats exist to describe intermediate states of processing, for example for the description of assembled contigs or variant calling\textsuperscript{41}. However, using these formats would make an \textit{a priori} assumption about the strategy of the bioinformatics pipeline that may not be universal; indeed, not all reported solutions involve assembling reads, or mapping them to reference genomes or databases (see, for example,\textsuperscript{42,43}).

### 2.2. Datasets origin

Three main sources of data for creating a benchmark dataset were identified. The first is to simulate the output (reads) \textit{in silico} using an input sequence of a resistant pathogen and a specialised software. The second is to use the archived output of previously performed experiments that are available in different repositories. The third is to perform NGS experiments on biological samples.

Although the disadvantage of simulating \textit{in silico} data is obvious (it is not ‘real’), there are some substantial advantages: it is a lot cheaper than performing sequencing runs, a lot faster, and can be applied to any genome previously sequenced. Thus, many more potential scenarios can be tested, for which the ground truth is well-established (i.e., the annotation of the genome reference that is used: different species, different classes of AMR, different localization of AMR), which usually cannot be done by actually sequencing them. Finally, it is also potentially ‘safer’ to do this for pathogenic bacteria for which high biosafety levels would be required to sequence in a laboratory. However, a major drawback is that simulating variation the way nature evolves is very challenging – genetic variation happens in places in the genome where it is hardest to find.

Many methods and programs have been developed to simulate genetic data. Their use in this context is, in itself, an exercise of Open Science and mechanisms should be used to guarantee quality and reproducibility (see \textsuperscript{44}). In 2013, Peng \textit{et al.}\textsuperscript{45} developed the catalogue “Genetic Simulation Resources” (GSR, available at https://popmodels.cancercontrol.cancer.gov/gsr/) to help researchers compare and choose the appropriate simulation tools for their studies. However, after reviewing the software listed in the GSR catalogue, the authors realised that the quality and usefulness of published simulation tools varied greatly due to inaccessible source code, lack of or incomplete documentation, difficulties in installation and execution, lack of support from authors and lack of program maintenance\textsuperscript{46}. For these reasons, a defined checklist of features that may benefit end users was developed\textsuperscript{47}; the “GSR Certification Program” was developed and recently implemented into the GSR in order to assess simulation tools based on these criteria\textsuperscript{48}. Established criteria are grouped to attribute four “certificates” (https://popmodels.cancercontrol.cancer.gov/gsr/certification/):

- **Accessibility**: it ensures that the simulator is openly available to all interested users and is easy to install and use.
- **Documentation**: it ensures that the simulator is well documented so that users can quickly determine if the simulator provides needed features and can learn how to use it.
- **Application**: it ensures that the software simulator is peer-reviewed, is reasonably user-friendly to be useful to peer researchers, and has been used by researchers in the scientific community.
- **Support**: it ensures that the authors of the simulator are actively maintaining the simulator, addressing users’ questions, bug reports and feature requests.

As of December 2019, the GSR catalogue lists 148 simulators and many of them have been assessed for their compliance with the requirements in order to be certified. Obviously, not all of them are for simulation of NGS reads. In 2016 Escalona \textit{et al.}\textsuperscript{49} identified and compared 23 computational tools for the simulation of NGS data and established a decision tree for the informed selection of an appropriate NGS simulation tool for the specific question at hand.

By browsing the GSR catalogue, 20 out of 23 tools assessed by Escalona \textit{et al.} (45) have been recorded, including only one with the four “GSR certificates” (Table 1), i.e. the ART tool\textsuperscript{45}. Other tools not assessed by Escalona are also present in the GSR catalogue with certificates, like NEAT\textsuperscript{50} and VISOR\textsuperscript{51}.

For choice of the simulation methods and programs for NGS reads, the decision tree proposed by Escalona \textit{et al.} is robust. However, it should be complemented by “certification” steps and, in this respect, we encourage the use of the “certification” criteria established by the GSR Certification Program, to tackle the challenge of following agreed principles for rigorous, reproducible, transparent, and systematic benchmarking of omics tools, in line with those proposed by Mangul \textit{et al.}\textsuperscript{11}.

Using pre-existing experiments, from private or public repositories, ensures that the components of the dataset are representative of a real-life experiment, including the complete panel of real-life variabilities that are difficult to simulate. The main issues then are: a) there is a need to demonstrate that the experiment met the necessary quality criteria (see section 2.3); b) the “correct” value (i.e. the ‘ground truth’) for the experiment needs to be determined. This can be already described in the metadata associated with the record and/or determined (verified) \textit{a posteriori} – although this requires strict annotation of the experiment; c) it will not be possible (besides rare exceptions) to build datasets for the different platforms using the same initial samples.
Generating experiments specifically for the sake of a benchmark dataset has almost the same advantages and disadvantages as using pre-existing data. Additional advantages include a better capacity to determine the “ground truth” of each sample by ensuring access to the original pathogen, as well as the possibility to generate datasets for the different platforms while using the same samples, if the same pathogen/purified DNA is processed through the different protocols and instruments. This also allows better control of the quality aspects of the procedure performed, e.g. through the use of accredited laboratories who have therefore demonstrated by audits that they possess the necessary knowhow and expertise to create high-quality data. However, an additional disadvantage is that this process requires a substantial investment of time and resources (although this investment may be deemed worthwhile given the importance of the topic, and could benefit from the involvement of the instrument vendors).

Because each approach has advantages and disadvantages, the choice must be carefully considered, according to the purpose of the dataset, which will be discussed in section 3.

### 2.3. Quality metrics

The quality of the original sample and the wet laboratory procedures (e.g. DNA extraction, library preparation and sequencing) have a strong impact on the quality of the reads fed into the bioinformatics pipelines. Contamination, low amounts of reads passing the machine QC, higher error rates than normal, etc. can influence the output of bioinformatics pipelines. Usually, the pipelines are designed to be resilient to some extent to these variations.

<table>
<thead>
<tr>
<th>Tool</th>
<th>In GSR?</th>
<th>Accessibility</th>
<th>Documentation</th>
<th>Application</th>
<th>Support</th>
</tr>
</thead>
<tbody>
<tr>
<td>ART</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>ArtificialFastqGenerator</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>BEAR</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CuReSim</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>DWGSIM</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>EAGLE</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FASTQSim</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FlowSim</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GemSIM</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>Grinder</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mason</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>MetaSim</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>NeSSM</td>
<td>No</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pbsim</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pIRS</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>ReadSim</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>simhtsd</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>simNGS</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SimSeq</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SInC</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td></td>
<td>Yes</td>
</tr>
<tr>
<td>wgsim</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>XS</td>
<td>Yes</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Table 1. Analysis of the GSR certifications of the computational tools for the simulation of next-generation sequencing described in 48. See text for details.
Although understanding this resilience is important, we propose, as shown in Figure 1, to separate these considerations from resources meant for quality control and performance evaluation (questions 1, 2a and 2b) for two reasons: first, many of these factors are variable, heterogeneous, technology-specific, and can be implemented at different stages of the bioinformatics pipeline; attempting to incorporate them all in the same resource would be impractical and too costly. Second, pipelines implemented for regulatory or clinical decision-making will be incorporated into a larger quality assurance framework that will ensure the quality of the input until that step. Although examples exist of end-to-end NGS workflow validation (like in the case of WGS) where bioinformatics is one of the components, our approach emphasizes a process where each step is validated separately (see 53).

It is then crucial to closely follow the proposed quality control schemes, either published or in development, in particular for the upstream steps (DNA isolation, library extraction, sequencing, etc.), for example ISO/TC 34/SC 9/WG 25. From these, both the metrics and the thresholds that can be applied at the level of the reads should be identified (some of which may vary according to the sequencing methodology), such as percent of bases with quality scores over Q30, percent alignment and error rates of the positive control (if present), the number of reads after trimming, quality of the draft assembly (e.g. N50, number of contigs), etc. Tools exist that can provide a panel of quality metrics from FASTQ files, such as FASTQC (RRID: SCR_014583)4. It is important to include the quality metrics as metadata in the dataset samples.

For studies evaluating resilience (question 3), a variety of datasets are needed for the “low quality dimensions” to be tested. For example, datasets incorporating high error rates, contaminating reads, reads with lower Q-scores could be used to assess resilience of pipelines to quality issues that may or may not be detectable with standard QC pipelines. For this reason, the establishment of standard datasets for this type of benchmarking is a complex exercise and answering question 3 of Figure 1 should be attempted on a case-by-case basis, and may be better suited to individual studies. One way to harmonise the approach would be to use the datasets produced for questions 1 and 2 as a starting point, as there are tools that can add some extent of “noise” to existing good quality datasets.

2.4. Choice of bacteria/resistance to include
In the context of challenging/evaluating a bioinformatics pipeline for the detection of AMR genetic determinants, a very pragmatic approach could be the generation of random DNA sequences, to which particular sequences of interest are added (i.e. fragments of AMR genes). However, the genomic background of the bacteria (i.e. the “non-AMR related” sequences) might have a profound influence on the performance of the pipelines. For example, pipelines that include a contig assembly step will be affected by the frequency and level of repetitive sequences in the background genome, as well as its GC content. Some species also have genes that are similar at the sequence level to known AMR determinants that efficient pipelines must be able to distinguish.

In conclusion, the bacterial species included in the benchmark datasets, and the AMR genes they contain, need thus to be carefully selected, with the appropriate justifications. These are specific to the purpose of the dataset (Figure 1) and will be discussed in section 3.1–section 3.3 below.

2.5. Genomic and phenotypic endpoints
A pipeline processing sequencing information for AMR can produce two closely linked but conceptually different outputs: a) they can detect the genetic determinants of AMR (genomic endpoint), and in addition b) some can predict the AMR/susceptibility of the bacteria in the original sample (phenotypic endpoint).

In a clinical context, the phenotypic endpoint is the most relevant, as it provides the information that is most useful for the end users. Studies that evaluated AMR genotype to phenotype relationships have indicated that despite generally high correspondence, this can vary greatly between pathogens / case studies, and even for different antimicrobial agents within the same species. There are different reasons for discrepancies between phenotype and genotype, including the extent of the expression of the resistance determinants for the resistance to be conferred, and also relatively complex molecular pathways that can influence the eventual phenotype. In some cases, genes can also confer reduced susceptibility (i.e. increasing the concentration of an antimicrobial necessary for treatment) rather than resistance per se. A phenotypic endpoint may also be problematic due to the definition of “antibiotic resistance” in different settings, which can complicate the interpretation of results.

In practice, however, focusing on a genomic endpoint has many advantages:

- The end-point (determinant; gene or SNP) is better defined: presence or absence.
- The gene copy number can be calculated, this is important even if obtaining gene copy numbers with short read data remains pretty difficult.
- It provides high resolution information that is useful when many genetic determinants confer resistance to the same antimicrobials.
- It offers additional information to contribute to an evaluation of the history of the spread of AMR.
- It does not rely on breakpoints such as MICs, which may vary between human and animal bacterial isolates, or may not be available for some animals (or pathogens), or because it may be updated based on phenotypic scientific observations.
- Even in the cases of AMR determinants not being expressed (thus not leading to a resistance phenotype), this may be important to characterise/record for epidemiological purposes.

2.6. Benchmark datasets metadata
Besides the set of reads themselves, additional information needs to be associated with each sample in the dataset, not for
the benchmarking per se but its use for next benchmarking exercises.

Obviously, each sample needs to include a “true” value, i.e. the ‘ground truth’ to be used for comparison when evaluating the performance of the pipeline. For a genotypic endpoint, this would take the form of the name (with a reference to a database) of the AMR determinants present. If real-life samples are used, the phenotypic information should be included, on top of the genotypic endpoint.

Public resources and repositories are available to host both the data and the metadata, and should be used as appropriate for the sake of transparency, obsolescence and traceability of the datasets of the benchmark resource. In practice, this means:

- The NGS reads data should be hosted in one of the International Nucleotide Sequence Database Collaboration (INSDC, RRID:SCR_011967) sequence reads archives⁶⁰, compiling the metadata information as appropriate.
- For simulated reads, this information should include the simulation tool used (source, version, parameters).
- For simulated reads, the “input” sequence(s) should be a closed genome, and any additional genes, that should be available in INSDC sequence archives⁶¹, and the record ID(s) included in the reads metadata information. Optimally, the closed genomes should be linked to a “real” sample in the INSDC BioSample database.
- For real experiments, the originally sequenced sample should be present/submitted in the INSDC BioSample database⁶², with all the appropriate metadata information (including identified resistances and the MIC(s) determined according to the standard culture-based evaluation methods).

### 3. Design of the scope-specific benchmark resources

Two main use cases for benchmarking resources have been discussed, i.e. single isolates and mixed samples, here summarised in sections 3.1-3.2 and 3.3, respectively.

#### 3.1. Is the bioinformatics pipeline performing according to (agreed) minimum standards?

The scope of this benchmark resource is to address the questions of validation, implementation and quality control over time (i.e. following any change in the pipeline or the environment on which it is executed). The dataset required for this should be compiled based on an agreed “minimum” standard, i.e. thresholds for the acceptance values of certain performance metrics for the bioinformatics pipeline in the context of the detection of AMR determinants, no matter the exact final use of the information produced.

This evaluation of performance should be based on challenging the pipeline with input representing a carefully selected set of resistance determinants and bacterial hosts. These sets of NGS reads should be fully characterised regarding their genetic content and serve as (in silico) reference materials for the validation and quality control of the bioinformatics component of the methods (see, for other host models, ⁶⁶,⁶⁷).

To maintain this necessary control on the genetic content of the reads, the dataset could be composed exclusively of simulated experiments. Synthetic artificial reads can be generated on a large scale in a harmonised manner and most importantly allow full control on the content. Alternatively, real sequencing datasets could be used, which would be extremely relevant for cases where the presence/absence of some AMR determinants has been established using consolidated classical molecular-biology-based methods and/or first generation-sequencing (e.g. PCR and/or Sanger sequencing). Both approaches enable the generation of datasets for which the ‘ground truth’ is well-established.

For the choice of resistances and bacterial species to be included, it is proposed to select them based on three sources, based on their current public health relevance and regulatory frameworks:

- The WHO’s list of antibiotic-resistant “priority pathogens”⁶⁸.
- The AMR reporting protocol for the European Antimicrobial Resistance Surveillance Network (EARS-Net)⁶⁹.
- The Commission Implementing Decision of 12 November 2013 on the monitoring and reporting of AMR in zoonotic and commensal bacteria⁷⁰.

Table 2 shows the combination of these three lists, in terms of both the bacterial species and the antibiotics mentioned.

It is important to highlight that the combination of these three lists still leaves important regulatory gaps, and should be complemented by the World Organisation for Animal Health (OIE, RRID:SCR_012759) list of antimicrobial agents of veterinary importance¹ or others². However, the lists do not mention specific species associated to each antibiotic, and these should be selected by the appropriate experts for the context of this benchmark resource. In practice, the generation of reference sequencing datasets should focus on:

1. Pathogens in Table 2 for which high-quality and complete reference genome sequences are available. See, for example, the FDA-ARGOS database¹¹ and the NCBI RefSeq Genomes database (RRID:SCR_003496).
2. Known genetic determinants for the resistance against the antibiotics in Table 2, using available resources¹²,¹³. If more than one determinant is associated with a resistance phenotype, one possibility is to collect them all; expert knowledge and empirical evidence on the relative contribution of different genes to the phenotypes, from published large-scale studies (e.g. ⁷⁴) can also be used to objectively reduce the list of determinants to include for a given antibiotic.
<table>
<thead>
<tr>
<th></th>
<th>Acinetobacter baumannii</th>
<th>Campylobacter coli</th>
<th>Campylobacter jejuni</th>
<th>Enterococcus faecalis</th>
<th>Enterococcus faecium</th>
<th>Escherichia coli</th>
<th>Haemophilus influenzae</th>
<th>Helicobacter pylori</th>
<th>Klebsiella pneumoniae</th>
<th>Neisseria gonorrhoeae</th>
<th>Neisseria meningitidis</th>
<th>Pseudomonas aeruginosa</th>
<th>Salmonella spp.</th>
<th>Shigella spp.</th>
<th>Staphylococcus aureus</th>
<th>Streptococcus pneumoniae</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Amikacin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Amoxicillin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ampicillin</strong></td>
<td>b</td>
<td></td>
<td>b</td>
<td>b</td>
<td>b</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Azithromycin</strong></td>
<td></td>
<td></td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cefepime</strong></td>
<td></td>
<td></td>
<td>b</td>
<td></td>
<td>b</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cefotaxime</strong></td>
<td>b</td>
<td></td>
<td>b</td>
<td>c</td>
<td>b</td>
<td>c</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cefoxitin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ceftazidime</strong></td>
<td>b</td>
<td></td>
<td>b</td>
<td>b</td>
<td>b</td>
<td>c</td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ceftriaxone</strong></td>
<td></td>
<td></td>
<td>b</td>
<td>b</td>
<td>b</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Chloramphenicol</strong></td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ciprofloxacin</strong></td>
<td>b</td>
<td>a,c</td>
<td>a,c</td>
<td>c</td>
<td>c</td>
<td>b</td>
<td>c</td>
<td>b</td>
<td>a</td>
<td>b</td>
<td>a</td>
<td>a</td>
<td>b</td>
<td></td>
<td>a</td>
<td>a</td>
</tr>
<tr>
<td><strong>Clarithromycin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>a</td>
<td></td>
<td></td>
<td></td>
<td>b</td>
<td>a</td>
<td>b</td>
<td>c</td>
<td></td>
<td></td>
<td>a</td>
</tr>
<tr>
<td><strong>Cloxacillin</strong></td>
<td></td>
<td>b</td>
<td>b</td>
<td>b</td>
<td></td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>a</td>
</tr>
<tr>
<td><strong>Colistin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>b</td>
<td>b</td>
<td>b</td>
<td>b</td>
<td></td>
<td>a</td>
<td>a</td>
<td>a</td>
<td></td>
<td>a</td>
<td></td>
</tr>
<tr>
<td><strong>Daptomycin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dicloxacillin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ertapenem</strong></td>
<td>a</td>
<td></td>
<td>a,b</td>
<td>a,b</td>
<td>a</td>
<td>a</td>
<td>a</td>
<td>a</td>
<td></td>
<td>a</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Erythromycin</strong></td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td>b</td>
<td>a</td>
<td>a</td>
<td></td>
<td></td>
<td></td>
<td>a</td>
</tr>
<tr>
<td><strong>Flucloxacillin</strong></td>
<td></td>
<td>b</td>
<td>b</td>
<td>b</td>
<td></td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>a</td>
<td>a</td>
<td></td>
<td></td>
<td></td>
<td>a</td>
</tr>
<tr>
<td><strong>Gentamicin</strong></td>
<td>b</td>
<td>c</td>
<td>c</td>
<td>b,c</td>
<td>b,c</td>
<td>b</td>
<td>b</td>
<td>b</td>
<td>c</td>
<td></td>
<td>a</td>
<td>b</td>
<td></td>
<td></td>
<td>a</td>
<td>b</td>
</tr>
<tr>
<td><strong>Imipenem</strong></td>
<td>a,b</td>
<td></td>
<td>a,b</td>
<td>a,b</td>
<td>a,b</td>
<td>a,b</td>
<td>a,b</td>
<td>a,b</td>
<td>a,b</td>
<td></td>
<td>a</td>
<td></td>
<td>a</td>
<td></td>
<td></td>
<td>a</td>
</tr>
<tr>
<td><strong>Levofloxacin</strong></td>
<td>b</td>
<td>a</td>
<td>a</td>
<td>b</td>
<td>b</td>
<td>b</td>
<td>a</td>
<td>b</td>
<td>a</td>
<td>c</td>
<td>a</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td>c</td>
</tr>
<tr>
<td><strong>Linezolid</strong></td>
<td>b,c</td>
<td></td>
<td>b,c</td>
<td></td>
<td></td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>a</td>
<td>a</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Meropenem</strong></td>
<td>a,b</td>
<td></td>
<td>a,b</td>
<td>a,b</td>
<td>a,b</td>
<td>a,b</td>
<td>a,b</td>
<td>a,b</td>
<td>a,b</td>
<td></td>
<td>a</td>
<td>a</td>
<td></td>
<td></td>
<td></td>
<td>a</td>
</tr>
<tr>
<td><strong>Methicillin</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>a</td>
<td>a</td>
<td></td>
<td></td>
<td></td>
<td>a,b</td>
</tr>
<tr>
<td><strong>Moxifloxacin</strong></td>
<td></td>
<td></td>
<td>b</td>
<td>b</td>
<td></td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>a</td>
<td></td>
<td></td>
<td></td>
<td>b</td>
</tr>
<tr>
<td><strong>Nalidixic acid</strong></td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>a</td>
<td>a</td>
<td></td>
<td></td>
<td></td>
<td>c</td>
</tr>
</tbody>
</table>

Table 2. Summary of the bacterial species and antibiotics resistances mentioned in the three lists discussed in the text. a: WHO's list of antibiotic-resistant “priority pathogens”, b: EARS-Net reporting protocol for 2018. c: Commission Implementing Decision 2013/652/EU.
<table>
<thead>
<tr>
<th>Bacteria/Resistances</th>
<th>Acinetobacter baumannii</th>
<th>Campylobacter coli</th>
<th>Campylobacter jejuni</th>
<th>Enterococcus faecalis</th>
<th>Enterococcus faecium</th>
<th>Escherichia coli</th>
<th>Haemophilus influenzae</th>
<th>Helicobacter pylori</th>
<th>Klebsiella pneumoniae</th>
<th>Neisseria gonorrhoeae</th>
<th>Pseudomonas aeruginosa</th>
<th>Salmonella spp.</th>
<th>Shigella spp.</th>
<th>Staphylococcus aureus</th>
<th>Streptococcus pneumoniae</th>
</tr>
</thead>
<tbody>
<tr>
<td>Netilmicin</td>
<td>b</td>
<td>b</td>
<td>b</td>
<td>b</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Norfloxacin</td>
<td></td>
<td>b</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ofloxacin</td>
<td>a</td>
<td>a</td>
<td>b</td>
<td>b</td>
<td>a</td>
<td>a</td>
<td>a</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oxacillin</td>
<td></td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Penicillin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>a,b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Piperacillin</td>
<td></td>
<td>b</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Polymyxin B</td>
<td>b</td>
<td></td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quinupristin/ Dalfopristin</td>
<td>c</td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rifampin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Streptomycin</td>
<td>c</td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sulfamethoxazole</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Teicoplanin</td>
<td>b,c</td>
<td></td>
<td>b,c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tetracycline</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tigecycline</td>
<td>c</td>
<td>c</td>
<td>c</td>
<td>b,c</td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tobramycin</td>
<td>b</td>
<td></td>
<td>b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>b</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Trimethoprim</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>c</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Vancomycin</td>
<td>b,c</td>
<td>a,b,c</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

3. Combinations of (1) and (2) present in at least one of the chosen lists (see cells in Table 2) (see section 2.3).

The availability of reference datasets for which the ground truth is known, i.e. the composition of AMR determinants within the sample (whether SNPs, genes, or more complex features) is well-established, allows to compare the output of bioinformatics pipelines to evaluate their performance. The endpoint considered for this benchmark is thus genotypic (see section 2.5), i.e. the proper detection and identification of genomic AMR determinants is evaluated. The reference datasets for each pathogen should be carefully chosen and characterised to ensure all present AMR determinants are carefully recorded.

Several classical performance metrics used traditionally for method performance evaluation can then be used to describe performance of the pipeline, such as sensitivity, specificity, accuracy, precision, repeatability, and reproducibility. Because of the selection of this subset of bacteria/resistances and their immediate clinical and regulatory importance, an important performance metric to be evaluated is accuracy, i.e. the likelihood that results are correct. Definitions for accuracy and other performance metrics should be carefully considered and tailored to the genomics context (for example, “reproducibility”, could be evaluated as the result of running the same bioinformatics pipeline, with the same datasets, implemented in different systems).

For all performance metrics, the minimum acceptable values should be subsequently determined once the outputs of real benchmarking exercises considering all the aspects described in this article are available. This will allow to enforce thresholds.
that pipelines should obtain. Such an approach focusing on performance-based evaluation offers a robust framework for pipeline validation that is more flexible than focusing all efforts on single pipelines or sequencing technologies. Scientists should be able to choose the pipeline best suited to their own needs, whether commercial, open-source, web-based, etc., as long as it conforms to minimum agreed upon performance standards, evaluated by analyzing the community AMR benchmark datasets that are created. This also offers flexibility with respect to the currently quickly evolving sequencing technologies for which it is not always clear yet which algorithmic approaches will become community standards, allowing different data analysis methodologies if minimum performance is demonstrated.

When generated, the benchmark should be deployed on a dedicated (and sustainably maintained) platform that includes all the links to the data (see section 2.6) and a description of all the steps/decisions that were taken to generate it. It is also important to implement, from the start, a clear version control system for the benchmark resource, in order to properly document the changes over time, and the exact versions used at the different times that the resource is used. In addition to the unique accession numbers of the individual samples in their respective repositories, the dataset as a whole should have a unique identifier (e.g. a DOI) that changes when any modification is made. The versioning should also allow access to and use of any previous versions of the resource, even after being updated.

This minimal dataset contains, by definition, a limited number of species and may lack pathogens of clinical importance (for example, Mycobacterium tuberculosis, for which WGS-based approaches have shown particular advantages, see 76,77). A full validation exercise for a specific pipeline, applied to a specific context, will need additional samples that complement the resource described in this section with the appropriate species/resistances. These datasets may, for example, be taken from the resources described in the following sections, that focus on evaluating the actual performance of methods in broader contexts by gathering the many datasets necessary to do so.

3.2. What is the quality of the information produced by the bioinformatics pipeline (prediction of resistance)?

The scope of this benchmark resource is to identify gold standards for bioinformatics pipelines, in this case linked to the specific use of predicting resistance/susceptibility of a pathogen.

There is a step between identifying the determinants of AMR and predicting resistance, which is not always straightforward as factors such as expression of the AMR gene may affect the prediction9,24. For this reason, and because it is conceptually closer to the information that is acted upon, the endpoint for this benchmark should be phenotypic. In addition, the dataset should be composed of real NGS experiments, since artefacts and variations are more complex in real sequencing reads than in simulated reads, a factor crucial to consider for this scope that focuses on accuracy.

To minimise the need of extensive resources to produce these “real” datasets, we propose to focus on re-using experiments previously performed under standardised conditions. A great source of data are the published ring trials; these have the additional advantage of providing an accurate characterisation of the sequenced samples, since the same original samples are sequenced many times by different laboratories. If needed, the data generated by single-site studies can also be evaluated, although in this case the issue of the correct characterisation of the samples (their “true” resistance patterns) should be addressed. One possibility is to use studies performed in a hospital setting, linked to clinical outcome (for example,4), or where sufficient information is available to evaluate the way the susceptibility testing was performed.

In practice, this would mean:

1. Performing an extensive review of the published literature to identify studies, ring trials, and proficiency testing that meet the criteria (focused on the detection of AMR using NGS, starting from a “real” sample). Table 3 provides a non-exhaustive list of recent references to be used as a starting point, together with reports from national and international reference laboratories dealing with AMR (see for example, the external quality assessment reports from the EU Reference Laboratory – Antimicrobial Resistance).

2. Assessing whether the raw sequencing output for the projects meet the FAIR principles (Findability, Accessibility, Interoperability, and Reusability)9, and are retrievable from publicly available repositories – even if they are access controlled. If not fully open, the corresponding authors should be contacted and asked whether the data could be obtained and deposited in long-term archives (e.g. Zenodo (RRID: SCR_004129), EuDat and/or the European Nucleotide Archive (ENA, RRID:SCR_006515) depending on the deposited data).

These datasets would then be used to test and compare the different bioinformatics pipelines in order to calculate the accuracy of their phenotypic predictions. Although not exhaustive, these datasets should cover the most relevant “real-life” cases, as they warranted their inclusion into a ring trial, with the associated resources committed to produce the data. The final size and composition (species, resistances) of the dataset would depend on what is provided by the available projects; ad hoc ring trials could be organised to cover eventual important gaps in species and/or resistance.

Although the chosen endpoint is mostly phenotypic, the purpose is to evaluate bioinformatics pipelines that process information at the sequence level, so it was agreed that there was little added value of inserting resistant samples (based on a characterised or inferred phenotype) for which the resistance mechanism is still unknown. In any case, it is improbable that these cases would have been included in ring trials projects.
Although the performance metrics described in Section 3.1 apply and are relevant in this case, the main performance metric for this benchmark is the accuracy. Because of the difficulty of predicting the link between the presence of AMR determinants and their impact on the pathogen susceptibility to the antimicrobial agents, the target accuracy is expected to be lower than for a genotypic endpoint. Both false positives and false negatives can be an issue when the information is used for clinical intervention, so a sufficient amount of “borderline” cases should be included, and both sensitivity and specificity evaluated. It is also possible to consider attaching different relative costs for false positives and false negatives when evaluating the accuracy metrics.

**Table 3.** Non-exhaustive list of sample studies to be analysed for the availability of FAIR raw reads data, to include in the benchmark resource.

<table>
<thead>
<tr>
<th>Pathogens</th>
<th>Study</th>
<th>Year</th>
<th>Study type</th>
<th>Ref</th>
</tr>
</thead>
<tbody>
<tr>
<td><em>Clostridium</em> (<em>Clostridioides</em>) <em>difficile</em></td>
<td>Berger <em>et al.</em></td>
<td>2019</td>
<td>ring trial</td>
<td>80</td>
</tr>
<tr>
<td><em>Neisseria meningitidis</em></td>
<td>Bogaerts <em>et al.</em></td>
<td>2019</td>
<td>validation study</td>
<td>53</td>
</tr>
<tr>
<td><em>Salmonella enterica</em></td>
<td>Mensah <em>et al.</em></td>
<td>2019</td>
<td>single study</td>
<td>81</td>
</tr>
<tr>
<td><em>Enterobacteriales</em></td>
<td>Ruppé <em>et al.</em></td>
<td>2019</td>
<td>single study</td>
<td>58</td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>Stubberfield <em>et al.</em></td>
<td>2019</td>
<td>single study</td>
<td>82</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Deplano <em>et al.</em></td>
<td>2018</td>
<td>ring trial</td>
<td>83</td>
</tr>
<tr>
<td><em>Brucella melitensis</em></td>
<td>Johansen <em>et al.</em></td>
<td>2018</td>
<td>ring trial</td>
<td>84</td>
</tr>
<tr>
<td><em>Salmonella enterica</em></td>
<td>Neuert <em>et al.</em></td>
<td>2018</td>
<td>single study</td>
<td>85</td>
</tr>
<tr>
<td><em>Salmonella, Campylobacter</em></td>
<td>Pedersen <em>et al.</em></td>
<td>2018</td>
<td>proficiency testing</td>
<td>86</td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>Pietsch <em>et al.</em></td>
<td>2018</td>
<td>single study</td>
<td>87</td>
</tr>
<tr>
<td><em>Enterococcus faecium, Enterococcus faecalis</em></td>
<td>Tyson <em>et al.</em></td>
<td>2018</td>
<td>single study</td>
<td>88</td>
</tr>
<tr>
<td><em>Actinobacillus pleuroneumoniae</em></td>
<td>Bossé <em>et al.</em></td>
<td>2017</td>
<td>single study</td>
<td>89</td>
</tr>
<tr>
<td><em>Klebsiella pneumoniae</em></td>
<td>Brhelova <em>et al.</em></td>
<td>2017</td>
<td>single study</td>
<td>90</td>
</tr>
<tr>
<td><em>Salmonella enterica</em></td>
<td>Carroll <em>et al.</em></td>
<td>2017</td>
<td>single study</td>
<td>91</td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>Day and al.</td>
<td>2016</td>
<td>single study</td>
<td>92</td>
</tr>
<tr>
<td><em>Salmonella spp., Escherichia coli, Staphylococcus aureus</em></td>
<td>Hendriksen <em>et al.</em></td>
<td>2016</td>
<td>proficiency testing</td>
<td>93</td>
</tr>
<tr>
<td><em>Salmonella</em></td>
<td>McDermott <em>et al.</em></td>
<td>2016</td>
<td>single study</td>
<td>94</td>
</tr>
<tr>
<td><em>Staphylococcus aureus, Enterococcus faecium, Escherichia coli, Pseudomonas aeruginosa</em></td>
<td>Mellmann <em>et al.</em></td>
<td>2016</td>
<td>single study</td>
<td>78</td>
</tr>
<tr>
<td><em>Staphylococcus aureus, Mycobacterium tuberculosis</em></td>
<td>Bradley <em>et al.</em></td>
<td>2015</td>
<td>single study</td>
<td>42</td>
</tr>
<tr>
<td><em>Escherichia coli</em></td>
<td>Tyson <em>et al.</em></td>
<td>2015</td>
<td>single study</td>
<td>95</td>
</tr>
<tr>
<td><em>Mycobacterium tuberculosis</em></td>
<td>Walker <em>et al.</em></td>
<td>2015</td>
<td>single study</td>
<td>76</td>
</tr>
<tr>
<td><em>Campylobacter jejuni, Campylobacter coli</em></td>
<td>Zhao <em>et al.</em></td>
<td>2015</td>
<td>single study</td>
<td>96</td>
</tr>
<tr>
<td><em>Pseudomonas aeruginosa</em></td>
<td>Koos <em>et al.</em></td>
<td>2014</td>
<td>single study</td>
<td>97</td>
</tr>
<tr>
<td><em>Staphylococcus aureus</em></td>
<td>Gordon <em>et al.</em></td>
<td>2013</td>
<td>single study</td>
<td>98</td>
</tr>
<tr>
<td><em>Escherichia coli, Klebsiella pneumoniae</em></td>
<td>Stoesser <em>et al.</em></td>
<td>2013</td>
<td>single study</td>
<td>99</td>
</tr>
<tr>
<td><em>Staphylococcus aureus, Clostridium difficile</em></td>
<td>Eyre <em>et al.</em></td>
<td>2012</td>
<td>single study</td>
<td>100</td>
</tr>
<tr>
<td><em>Salmonella typhimurium, Escherichia coli, Enterococcus faecalis, Enterococcus faecium</em></td>
<td>Zankari <em>et al.</em></td>
<td>2012</td>
<td>single study</td>
<td>101</td>
</tr>
<tr>
<td><em>Salmonella</em></td>
<td>Cooper <em>et al.</em></td>
<td>2020</td>
<td>single study</td>
<td>102</td>
</tr>
</tbody>
</table>
Once selected and combined, the data should be separated by NGS platform, and by species and antibiotic. Because this benchmarking aims at evaluating and comparing performance of methods, which are continuously developed and optimised, against a large and constantly expanding dataset, it is crucial to define an environment where the AMR community can establish a continuous benchmarking effort. Within this platform, pipelines would be compared simultaneously based on up-to-date datasets, under the same conditions, and over time. Constantly updating and adding to the reference datasets is important both to keep up with the evolution of the knowledge/realality in the field, and to avoid that pipelines are developed that are optimised to specific datasets only.

One option is OpenEBench (Open ELIXIR Benchmarking and Technical Monitoring platform), which is developed under the ELIXIR-EXCELERATE umbrella in order to provide such a platform. In this framework, in addition to compiling the data resources to be included (as described above), and whatever the platform chosen, there will be the need for efforts to:
- Establish guidelines for input and output formats (and, in the case of the phenotypic endpoint, an agreed ontology for the conclusions).
- Encouraging a “FAIR” implementation of the pipelines themselves, to increase the number of pipelines accessible for the benchmarking platform, and for interested end users to retrieve and implement in-house.

Provisions should be included to allow the possibility to evaluate, in this context, pipelines that cannot be made “FAIR” based on intellectual property rights, institutional policies or available resources.

A final step will be to communicate these efforts within the scientific community and the potential end users, as well as to demonstrate the added value of this “live” benchmark resource to ensure that future studies (in particular, their pipelines and the datasets they generate) are efficiently integrated in the platform.

### 3.3. What is the quality of the information produced by the bioinformatics pipeline (mixed samples)?

Many gaps exist in the scientific understanding of antibiotic resistance development and transmission, making it difficult to properly advise policy makers on how to manage this risk. There is strong evidence that a multitude of resistance genes in the environment have not yet made it into pathogens; under -

The resistome is usually derived from a sample containing a complex microbial community (see 111–113 for recent examples). For this reason, the approaches from the ongoing Critical Assessment of Metagenome Interpretation (CAMI) could be considered when organising the community around this challenge.

In practice, this means an effort to engage and coordinate the community of bioinformatics pipelines designed to predict the resistome of a sample in order to:

1. Design the scope of the challenge, including the relevant metrics for performance evaluation. For this, “accuracy”, the main metrics for the previous two benchmarks, may not be the most appropriate, and the focus should be placed, e.g., on “recall” and “precision”.
2. Describe the microbial communities (i.e. microbial abundance profiles and their typical AMR gene profiles) most relevant for the determination/monitoring of the resistome, in order to generate congruent datasets that accurately represent real-life samples. Of particular interest, for which validation will eventually be a prerequisite, are blood, serum, saliva etc., i.e. the types of samples clinical microbiology laboratories and national reference centres/laboratories typically process.
3. Identify both the microbial genomes and the resistance determinants (as single genetic determinants or plasmids) necessary to generate the profiles identified in (2). As stated in section 3.1, the genomes should be well analysed to ensure no lack of, or an adequate characterisation of, AMR determinants. This is crucial in order to establish a resistome “ground truth” for the generated datasets.
4. Combine these sequences, as appropriate, to generate the benchmark datasets, using appropriate tools (such as CAMISIM, developed as part of the CAMI challenge).

The community should decide whether (or at what stage) the use of real data can also be considered in the challenge. As for purified bacteria (see Table 3), many studies have been published as potential sources of raw data. These studies can also be used as a source of information to define the relevant profiles (point 2 above). Recent studies include resistome
the determination in samples from drinking water\textsuperscript{106,117}, wastewater \textsuperscript{108,119}, hospital wastewater \textsuperscript{120,121}, human gut \textsuperscript{111,122}, sewage\textsuperscript{123}, to name a few. In the benchmarking platform, the datasets (and the calculated pipeline performances) should be separated by the type of source they originate from or simulate. Another important point for this scope is the detection of minority populations and the correct normalisation of the samples to be analysed\textsuperscript{124}.

Conclusions
The scientific community quickly adopted the new NGS technologies to develop methods that can efficiently detect, identify and characterise genetic determinants of AMR. In parallel with these research uses, NGS technologies can have immediate impacts on how AMR is diagnosed, detected and reported worldwide, complementing etiologic agent diagnosis, clinical decision making, risk assessment and established monitoring frameworks\textsuperscript{3,123–127}.

For this application and in general, there are great challenges in the implementation of NGS-based methods for public decision-making. Capacity building and its cost is of course a factor, but recent surveys show that capacity development is ongoing in many countries\textsuperscript{28}. A greater concern is the interpretation of the produced genomic data into meaningful information that can be acted upon or used for regulatory monitoring, in great part because of the important bioinformatics component of these methods.

The difficulties posed by this reliance on bioinformatics processes are many, and include:

- The specific expertise needed for their implementation and maintenance, which is still limited compared to the needs of routine testing environments.
- The lack of harmonisation in their design, as the same sequencer output can be processed to produce the same target information by pipelines that either follow the same general strategy, with different tools for the individual steps, or completely different strategies entirely (see \textsuperscript{128}).
- The constant, rapid evolution of the fields of informatics and bioinformatics, which makes uneasy (or even unwise) to “freeze” a harmonised, validated, implemented pipeline with the same components in the same environment over long periods of time.
- For AMR, as for other fields, the pipelines (and their performance metrics) are built based on a \textit{a priori} scientific knowledge, in this case the genetics of resistance, which is constantly progressing.

In this document, we propose a way through these difficulties with a transparent, performance-based evaluation approach to assess and demonstrate that pipelines are fit-for-purpose and to ensure quality control. The discussions, initiated in 2017\textsuperscript{17}, have involved experts in different fields: human health, animal health, food and environmental monitoring, and general bioinformatics.

The approach is two-fold: first, an agreed-upon, limited dataset to contribute to performance-based control of the pipeline implementation and their integration in quality systems. We propose selection criteria for this common dataset based on bacterial species and resistances relevant to current public health priorities (see section 3.1).

Second, a community-driven effort to establish a “live” benchmarking platform where both the datasets and the bioinformatics workflows are available to the community according to the FAIR principles. After an initial investment of resources to establish the rules and integrate the existing resources, a proper engagement of the community will be needed to ensure that both the datasets and the workflows will constantly be updated, with live monitoring of the resulting comparative performance parameters. For this, two main use cases were identified, each necessitating its own platform: the analysis of isolates (with a focus on the prediction of resistance, see section 3.2), and the analysis of mixed samples (with a focus on the interpretation of the resistome, see section 3.3).

To ensure acceptance of this approach by regulators and policy-makers, the conclusions and the roadmap proposed in this document should be complemented (and, if necessary, revised) with the continuous involvement of all relevant actors in the field, including (but not limited to) the scientific community (see \textsuperscript{13} and \textsuperscript{114} as excellent examples of defining principles for benchmarking, and a roadmap for software selection, respectively, to guide researchers), the collaborative organisation and platforms active in the field (e.g. the European Committee on Antimicrobial Susceptibility Testing (EUCAST), the Joint Programming Initiative on Antimicrobial Resistance (JPIAMR), the Global Microbial Identifier (GMI), the European Society of Clinical Microbiology and Infectious Diseases and its Study Groups (ESCMID)), regulatory agencies (e.g. the European Food Safety Authority (EFSA, RRID:SCR_000963), the European Centre for Disease Prevention and Control (ECDC), European Union reference laboratories and their networks (e.g. the EURL AR and the EURLs for the different pathogens) and the existing bioinformatics infrastructures (e.g. the European Bioinformatics Institute (EMBL/EBI), ELIXIR).

Such an approach would be a way to facilitate the integration of NGS-based methods in the field of AMR, and may be a case study on how to approach the overlapping challenges in other potential fields of applications, including some at high level in policy agendas (food fraud, genetically modified organism detection, biothreats monitoring for biodefense purposes, etc.).

Disclaimer
The contents of this article are the views of the authors and do not necessarily represent an official position of the European Commission or the U.S. Food and Drug Administration.

Data availability
No data is associated with this article.
Acknowledgments
We would like to thank Valentina Rizzi (EFSA) and Alberto Orgiazz (JRC) for their participation to the workshop discussions. The authors are also grateful to the following colleagues for their comments on the manuscript: Sigrid De Keersmaecker and Nancy Roosens (Sciensano) and Twedros Debebe (Biomes). We are also grateful to Laura Oliva for her invaluable help during the workshop.

References


Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text

125. EFSA Panel on Additives and Products or Substances used in Animal Feed (FEEDAP); Rychen G, Aquilina G, et al.: Guidance on the characterisation of microorganisms used as feed additives or as production organisms. EFSA J. 2018; 16(3). 
PubMed Abstract | Publisher Full Text | Free Full Text


127. European Centre for Disease Control (ECDC), European Food Safety Authority (EFSA); Van Walle I, et al.: EFSA and ECDC technical report on the collection and analysis of whole genome sequencing data from food-borne pathogens and other relevant microorganisms isolated from human, animal, food, feed and food/feed environmental samples in the joint ECDC-EFSA molecular typing database. EFSA Support Publ. 2019; 16(5). Publisher Full Text

PubMed Abstract | Publisher Full Text | Free Full Text
Open Peer Review

Current Peer Review Status:  ?  ?

Version 1

Reviewer Report 14 September 2021

https://doi.org/10.5256/f1000research.42277.r91069

© 2021 Abramova A et al. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Anna Abramova
Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden

Marcus Wenne
Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden

Petrillo and colleagues discuss approaches and associated challenges for establishing a performance-based benchmarking resource for antimicrobial resistance detection. The authors first describe general considerations and then provide scope-specific use cases. The paper represents a summary of the discussions held by experts in AMR and NGS-related fields during the JRC meeting. It is a relevant and important paper, and the initiative will be widely appreciated by the scientific community working with antimicrobial resistance. Overall, the paper is well-written, however, it would benefit from some additional clarifications and adjustments, which are explained in more detail in the comments below.

Introduction
  ○ Since the main focus of the paper is benchmarking, it would be beneficial to provide a short background on the previous benchmarking resources/initiatives in the introduction (e.g. Mangul et al., 2019, Sczyrba et al., 2017, etc).

Section 2
  ○ Paragraph 2: “In the conclusions of the previous article...”, it is confusing which article the authors refer to since reference 19 (Bellman et al., 2015) provided at the end of the sentence does not contain the cited text.

General considerations
  ○ Several important questions such as which tools to include in the benchmarking, should they be run with optimised or default parameters (e.g. default or customised database), and what performance metrics are to be used for evaluation - could be added to the "General discussion" to clarify and benefit in the understanding of the subsequent sections.

Section 2.1
  ○ This section discusses very important considerations when it comes to different sequencing technologies. Since sequencing technologies are constantly evolving perhaps it would be relevant to add some future perspectives, e.g. how to deal with emerging outperforming...
technologies.

○ Paragraph 2: From the sentence starting with “It is important, in this case...”, it is not clear whether the authors mean the bias among different platforms' outputs or outputs from the same platform.

Section 2.2

○ Apart from being in silico generated or obtained from a real-life sample, the data can come from different types of samples. In the case of metagenomics, it would be an important consideration for the evaluation of bioinformatics tools (i.e. a human gut sample or a soil sample would be characterised by a very different complexity).

○ Paragraph 7: “The main issues then are: a) there is a need to demonstrate that the experiment met the necessary quality criteria (see section 3.3)” - section 3.3 does not contain any information on the quality criteria.

○ Paragraph 11: “Because each approach has advantages and disadvantages, the choice must be carefully considered, according to the purpose of the dataset, which will be discussed in section 4.” - section 4 is missing.

Section 2.4

○ This is perhaps the most important section considering the focus of the paper on AMR detection, however, it is very concise and does not provide a good overview of the challenges (e.g. what type of AMR mechanisms to include, which pathogens to consider). These topics are described later in section 3.1 in the example of a particular use case. However, it would be beneficial to outline them in the General considerations section.

○ Paragraph 2: “These are specific to the purpose of the dataset (Figure 1) and will be discussed in section 4.1–section 4.3 below” - sections 4.1-4.3 are missing.

Section 2.5

○ To aid understanding it would be helpful to clarify genomic and phenotypic endpoint, perhaps by adding to the first sentence, e.g., “a) they can detect the genetic determinants of AMR (genomic endpoint), and in addition b) some can predict the AMR/susceptibility of the bacteria in the original sample (phenotypic endpoint).”

Section 3.1

○ Paragraph 4: “3. Combinations of (1) and (2) present in at least one of the chosen lists (see cells in Table 2), the sequences are combined and used as the input to simulate the reads using the appropriate tools (see section 3.2).” - maybe the authors meant section 2.3 instead of 3.2.

○ Paragraph 6: “The endpoint considered for this benchmark is thus genotypic (see section 3.5),” - section 3.5 is missing.

○ Paragraph 10: “When generated, the benchmark should be deployed on a dedicated (and sustainably maintained) platform that includes all the links to the data (see section 3.6)” - section 3.6 is missing.

Conclusions

○ The authors mention in the conclusion that they identified two main use cases for this benchmarking resource, each necessitating its own platform: single isolates and mixed samples. This could be expanded upon in the General considerations section to give the reader an understanding of the different challenges and approaches for the two use cases.
It is also implied, but not specifically stated, in sections 3.1 and 3.2 that they focus on single isolates. This only becomes clear when reading section 3.3.

○ Sections 4.1-4.3 are missing.

References

Is the topic of the opinion article discussed accurately in the context of the current literature?
Yes

Are all factual statements correct and adequately supported by citations?
Yes

Are arguments sufficiently supported by evidence from the published literature?
Yes

Are the conclusions drawn balanced and justified on the basis of the presented arguments?
Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: AMR, NGS data analysis, bioinformatics

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.

Author Response 16 Sep 2021

Mauro Petrillo, European Commission Joint Research Centre, Ispra, Italy

Dear Dr Abramova and Dr Wenne,

Thanks a lot for your valuable comments and suggestions that you have provided in the report.

We will address all of them, together with those of other reviewers, in order to provide a fully revised version of the manuscript.

Best regards,
Mauro Petrillo, on behalf of the authors.

**Competing Interests:** No competing interests were disclosed.

Author Response 09 Mar 2022

Mauro Petrillo, European Commission Joint Research Centre, Ispra, Italy

**Replies to:**
Anna Abramova, Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden
Marcus Wenne, Department of Infectious Diseases, University of Gothenburg, Gothenburg, Sweden

**REPLY:** Thanks for your comments, we have revised the whole manuscript and we hope it is now in line with your expectations.

**Introduction**

Since the main focus of the paper is benchmarking, it would be beneficial to provide a short background on the previous benchmarking resources/initiatives in the introduction (e.g. Mangul et al., 2019, Sczyrba et al., 2017, etc).

**REPLY:** Thanks the suggestion. We added them in the Conclusions section.

**Section 2**

Paragraph 2: “In the conclusions of the previous article...”, it is confusing which article the authors refer to since reference 19 (Bellman et al., 2015) provided at the end of the sentence does not contain the cited text.

**REPLY:** Thanks for spotting this error, which has been corrected.

**General considerations**

Several important questions such as which tools to include in the benchmarking, should they be run with optimised or default parameters (e.g. default or customised database), and what performance metrics are to be used for evaluation - could be added to the "General discussion" to clarify and benefit in the understanding of the subsequent sections.

**REPLY:** Section 3.1 was substantially rewritten to provide more information on the performance-based evaluation. Concretely, both tools and their parameters, should be open to the preferences and requirements of the end users. Certain groups might have a preference for certain tools because it is easier to implement for them, they have developed the tool themselves in-house, it’s freely available as open-source solutions or alternatively commercially available but with full customer support etc. As long as said tools are demonstrated to provide a certain minimum performance, they can be used since the benchmarking should focus on performance rather than enforcing a single pipeline to be used by all (which at any rate, would be unlikely, given the plethora of different sequencing technologies, platforms, and chemistries). The same logic applies to settings, for which certain groups may wish to extensively finetune certain settings but others may prefer to keep them at defaults. With respect to the actual performance metrics to be used,
more information was provided in the revised manuscript but we prefer redirecting to reference publications such as Kozyreva et al. (https://doi.org/10.1128/JCM.00361-17) for a more detailed explanation and example of how these could be implemented, since providing all that information would substantially enlarge the size of this paper.

Section 2.1
- This section discusses very important considerations when it comes to different sequencing technologies. Since sequencing technologies are constantly evolving perhaps it would be relevant to add some future perspectives, e.g. how to deal with emerging outperforming technologies.

**REPLY:** A sentence has been added to the end of the section indicating that implementation of new benchmark datasets should be prioritized if new and better technologies emerge.
- Paragraph 2: From the sentence starting with “It is important, in this case...”, it is not clear whether the authors mean the bias among different platforms' outputs or outputs from the same platform.

**REPLY:** Text has been modified to try to clarify that this means bias among the different platforms.

Section 2.2
- Apart from being in silico generated or obtained from a real-life sample, the data can come from different types of samples. In the case of metagenomics, it would be an important consideration for the evaluation of bioinformatics tools (i.e. a human gut sample or a soil sample would be characterised by a very different complexity).

**REPLY:** We have addressed this point in section 3, which was revised.
- Paragraph 7: “The main issues then are: a) there is a need to demonstrate that the experiment met the necessary quality criteria (see section 3.3)” - section 3.3 does not contain any information on the quality criteria.

**REPLY:** Should be 2.3 Text has been modified accordingly.
- Paragraph 11: “Because each approach has advantages and disadvantages, the choice must be carefully considered, according to the purpose of the dataset, which will be discussed in section 4.” - section 4 is missing.

**REPLY:** Should be 3. Text has been modified accordingly.

Section 2.4
- This is perhaps the most important section considering the focus of the paper on AMR detection, however, it is very concise and does not provide a good overview of the challenges (e.g. what type of AMR mechanisms to include, which pathogens to consider). These topics are described later in section 3.1 in the example of a particular use case. However, it would be beneficial to outline them in the General considerations section.

**REPLY:** The “General considerations” section has been expanded accordingly.
- Paragraph 2: “These are specific to the purpose of the dataset (Figure 1) and will be discussed in section 4.1–section 4.3 below” - sections 4.1-4.3 are missing.

**REPLY:** Should be 3.1-3.3. Text has been modified accordingly.
Section 2.5
○ To aid understanding it would be helpful to clarify genomic and phenotypic endpoint, perhaps by adding to the first sentence, e.g., “..a) they can detect the genetic determinants of AMR (genomic endpoint), and in addition b) some can predict the AMR/susceptibility of the bacteria in the original sample (phenotypic endpoint).”
REPLY: Added as suggested.

Section 3.1
○ Paragraph 4: “3. Combinations of (1) and (2) present in at least one of the chosen lists (see cells in Table 2), the sequences are combined and used as the input to simulate the reads using the appropriate tools (see section 3.2).” - maybe the authors meant section 2.3 instead of 3.2.
REPLY: Should be 2.3, text has been modified.
○ Paragraph 6: “The endpoint considered for this benchmark is thus genotypic (see section 3.5),” - section 3.5 is missing.
REPLY: Should be 2.5- Text has been modified accordingly
○ Paragraph 10: “When generated, the benchmark should be deployed on a dedicated (and sustainably maintained) platform that includes all the links to the data (see section 3.6)” - section 3.6 is missing.
REPLY: Should be 2.6. Text has been modified accordingly

Conclusions
○ The authors mention in the conclusion that they identified two main use cases for this benchmarking resource, each necessitating its own platform: single isolates and mixed samples. This could be expanded upon in the General considerations section to give the reader an understanding of the different challenges and approaches for the two use cases. It is also implied, but not specifically stated, in sections 3.1 and 3.2 that they focus on single isolates. This only becomes clear when reading section 3.3.
REPLY: A short introduction in section 3 has been added. The “General considerations” section has been expanded accordingly, too.

○ Sections 4.1-4.3 are missing.
REPLY: Should be section 3. Text has been modified accordingly.

Competing Interests: No competing interests were disclosed.
This manuscript describes a road map how to set up and conduct benchmarking to assess bioinformatics pipelines to detect AMR genes in three levels.

Overall, comments:
The manuscript is well-written but I find it in several paragraphs hard to comprehend the sentences as the authors contradict themselves. This needs to be address as the topic is important but it needs to be all clear.
I suggest to focus the paper on single isolate genomes rather than but this and metagenomics. It is really two separate technologies and will need different approaches. It is trying to explain all but fails really to in depth address metagenomics.

Specific comments:
- Page 4 1st paragraph: Describe other epidemiological traits alongside with the timeline and relatedness by merging the paragraphs “…such as virulence, resistance to antibiotics, typing and other adaptive traits…” to the same paragraph. I was missing the characterization of AMR genes in the initial lines as this is the focus and title of the paper.
- Page 4 introduction: I miss an explanation about “complex microbial communities”. I know this is metagenomics but the term needs to be introduced.
- Page 4 introduction: “… antimicrobial resistance (AMR) genetic determinants from NGS data…. This needs to be clarified if this include acquired antimicrobial resistance genes AND/ OR chromosomal point mutations. This is not clear what the approach includes.
- Page 5 2nd bullet: Clarify what is mean by resistome. I suggest to make it clear that this bullet deals with metagenomics.
- Page 5 last paragraph: “Bioinformatics pipelines are thus usually designed to handle the output of a specific platform, often in a certain configuration”. This is true but also the achilles heel of the further description where this is being contradicted.
- Fig 1: I miss the word “concordance to phenotype” as well as curation for scope 1.
- Page 6 2nd paragraph: “in practice, a prioritisation exercise should be made based on the capacity building efforts in testing laboratories”. Clarify why this is needed!
- Fig 2: The data could easily be explained in text – omit fig 2 or reference already published similar figures.
- Page 6 4th paragraph: I don't understand the concept. It was earlier explained that “Bioinformatics pipelines are thus usually designed to handle the output of a specific platform, often in a certain configuration” so, why compare the output of a certain pipeline from data generated from different platforms knowing that the result for certain platforms will be biased due to the low comparability of a certain pipeline.
- Page 6 5th paragraph: “The FASTQ format is a standard format in this context, which should be used in the benchmark resources; many tools exist to convert the raw data output files into this format in case of different platform outputs (see, for example, 39, 40) although, it should be noted, different tools may produce different results and this step should be carefully planned.” I find this a source for bringing in bias to the benchmarking. I find it hard to see how one can trust the analysis when bringing in variation which might not even be controlled.

- Page 7 1st, 2nd, 7th paragraph: I did it contradicting that its phrased that “Although the disadvantage of simulating in silico data is obvious (it is not ‘real’), there are some substantial advantages: it is a lot cheaper than performing sequencing runs, a lot faster, and can be applied to any genome previously sequenced.” and “However, a major drawback is that simulating variation the way nature evolves is very challenging – genetic variation happens in places in the genome where it is hardest to find.” And “although this requires strict annotation of the experiment; c) it will not be possible (besides rare exceptions) to build datasets for the different platforms using the same initial samples.” First of all, it’s not all that can prepare simulated datasets and secondly, its correct that it will never mimic nature, Thus, I don’t see why this is so heavily recommended.

- Page 9 1st paragraph: I miss N50, no of contigs etc.. to be mentioned as QC metrics.

- Page 9 2nd paragraph: Not easy to understand.

- Page 9 2.4 1st paragraph: “a very pragmatic approach could be the generation of random DNA sequences, to which particular sequences of interest are added (i.e. fragments of AMR genes). However, there is sufficient evidence that the genomic background of the bacteria (i.e. the “non-AMR related” sequences) can have a profound influence on the performance of the pipelines”. Contradiction – see Page 7 1st, 2nd, 7th paragraph.

- Page 9 6th paragraph: define “phenotypic endpoint”.

- Page 9 6th paragraph: “Studies that evaluated AMR genotype to phenotype relationships have indicated that despite generally high correspondence, this can vary greatly between pathogens / case studies, and even for different antimicrobial agents within the same species 57,58.” I need to be further elaborated – what do one trust the phenotypic data or detected genes.

- Page 9 intro to bullets: define “genomic endpoint”.

- Page 9 section 2.6: Agree that metadata is needed but it needs to be explained that its not needed for the benchmarking itself but for others to use the dataset for future exercises.

- Page 10 1st paragraph of section 3.1: explain what is meant by “agreed minimum standards”- what performance metrics.

- Page 10 3rd paragraph of section 3.1: I find it contradicting to Page 7 1st, 2nd, 7th paragraph.

- Page 10: WHO CIA has been updated – provide ref.
Is the topic of the opinion article discussed accurately in the context of the current literature?
Partly

Are all factual statements correct and adequately supported by citations?
Partly

Are arguments sufficiently supported by evidence from the published literature?
No

Are the conclusions drawn balanced and justified on the basis of the presented arguments?
Partly

**Competing Interests:** No competing interests were disclosed.

**Reviewer Expertise:** Microbiologist focusing on NGS and EQA/ benchmarking

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 16 Sep 2021

**Mauro Petrillo**, European Commission Joint Research Centre, Ispra, Italy

Dear Dr Hendriksen,

Thanks a lot for your valuable comments and suggestions that you have provided in the report.

We will address all of them, together with those of other reviewers, in order to provide a fully revised version of the manuscript.

Best regards,

Mauro Petrillo, on behalf of the authors.
Author Response 09 Mar 2022

Mauro Petrillo, European Commission Joint Research Centre, Ispra, Italy

Replies to Rene Hendriksen, National Food Institute, Technical University of Denmark, Bygning, Lyngby, Denmark.

Overall, comments
The manuscript is well-written but I find it in several paragraphs hard to comprehend the sentences as the authors contradict themselves. This needs to be address as the topic is important but it needs to be all clear. 
I suggest to focus the paper on single isolate genomes rather than but this and metagenomics. It is really two separate technologies and will need different approaches. It is trying to explain all but fails really to in depth address metagenomics.

REPLY: Thanks for your comments, we have revised the whole manuscript and we hope it is now in line with your expectations.

Specific comments
- Page 4 1st paragraph: Describe other epidemiological traits alongside with the timeline and relatedness by merging the paragraphs “....such as virulence, resistance to antibiotics, typing and other adaptive traits... to the same paragraph. I was missing the characterization of AMR genes in the initial lines as this is the focus and title of the paper.

REPLY: Paragraphs 1 and 2 have been merged, and reference to the use of this data for inferring AMR has been moved to early in paragraph 1 as suggested.

- Page 4 introduction: I miss an explanation about “complex microbial communities”. I know this is metagenomics but the term needs to be introduced.

REPLY: As requested, bullets on this page have been rewritten to introduce the “metagenome” terminology

- Page 4 introduction: “.... antimicrobial resistance (AMR) genetic determinants from NGS data.... This needs to be clarified if this include acquired antimicrobial resistance genes AND/ OR chromosomal point mutations. This is not clear what the approach includes.

REPLY: The bullets on page 4 have been modified to indicate that phenotype prediction relies on detection of both acquired ARGs and point mutations. We felt that this was a better place to define the types of genetic determinants associated with AMR

- Page 5 2nd bullet: Clarify what is mean by resistome. I suggest to make it clear that this bullet deals with metagenomics.

REPLY: This bullet has been rewritten to address clarity.

- Page 5 last paragraph: “Bioinformatics pipelines are thus usually designed to handle the output of a specific platform, often in a certain configuration”. This is true but also the achilles heel of the further description where this is being contradicted.

REPLY: We have rewritten section 3.1 to make clearer that validation of different pipelines should be performance-based, i.e. focus on their performance rather than enforcing a single pipeline to
be adopted by the community. Different sequencing technologies exist, but also for the same technology there exist differences in instruments and chemistries that potentially require specifically adapted pipelines to accommodate specific configurations. By building community benchmarking datasets for which the ground truth is well-established for those configurations, prioritizing dominant technologies, it becomes possible that different pipelines are used by different groups (even when both groups otherwise use exactly the same configuration), as long as those pipelines meet minimum agreed upon acceptance values for their performance.

- Fig 1: I miss the word “concordance to phenotype” as well as curation for scope 1.

**REPLY:** Sorry, we did not understand this point. Do you mean these concepts should be added to Figure 1? Or that what is reported in the figure 1 is inconsistent with what mentioned in the text?

- Page 6 2nd paragraph: “In practice, a prioritisation exercise should be made based on the capacity building efforts in testing laboratories” Clarify why this is needed!

**REPLY:** This has been reworded to indicate that it may be necessary if resource limitations are an issue.

- Fig 2: The data could easily be explained in text – omit fig 2 or reference already published similar figures.

**REPLY:** We added additional text to justify the presence of Figure 2.

- Page 6 4th paragraph: I don’t understand the concept. It was earlier explained that “Bioinformatics pipelines are thus usually designed to handle the output of a specific platform, often in a certain configuration” so, why compare the output of a certain pipeline from data generated from different platforms knowing that the result for certain platforms will be biased due to the low comparability of a certain pipeline.

**REPLY:** We provide here a clarification. Even though pipelines can be drastically different, e.g. made for different sequencing technologies or use completely different algorithmic approaches for a certain configuration (e.g. assembly-based or read-mapping based strategies), their final aim in the context of this manuscript considers the correct detection and identification of AMR determinants (whether SNPs, genes or more complex features), as quantified by validating their performance. Consequently, it is not the output of those pipelines themselves that will be directly compared, but rather the ability of said pipelines to correctly detect and identify AMR determinants. Whatever sequencing technology or bioinformatics methodology is applied, if a pipeline designed to detect AMR genes cannot properly detect and identify those genes, then said pipeline cannot be considered validated for AMR gene detection in a clinical or regulatory application. Contrarily, if said pipeline can correctly detect and identify those genes, then it could be applied in such contexts.

- Page 6 5th paragraph: “The FASTQ format is a standard format in this context, which should be used in the benchmark resources; many tools exist to convert the raw data output files into this format in case of different platform outputs (see, for example,39,40) although, it should be noted, different tools may produce different results and this step should be carefully planned.” I find this a source for bring in bias to the benchmarking. I find it hard to see how one can trust the analysis when bringing in variation which might not even be controlled.

**REPLY:** This is exactly what the generation of community benchmark datasets circumvents by providing reference datasets for which the ground truth is well-established. By starting from such samples, whether using reference genomes with known AMR determinants for which reads are simulated with error profiles modelled to mimic specific sequencing technologies, or alternatively using real samples where certain AMR determinants have been shown to be present/absent with
traditional methods (e.g. PCR and/or Sanger sequencing) subjected to sequencing by specific sequencing technologies, the resulting datasets can be analyzed with pipelines for which it is known which AMR determinants should be detected. If such an approach uncovers that certain variation and biases specific to certain sequencing technologies and/or configurations cannot be controlled for bioinformatically and negatively affect pipeline performance leading to missed detection (or alternatively false positive detections), said pipeline cannot be considered validated for AMR characterization in a clinical or regulatory application. We hope this clarifies.

- Page 7 1st, 2nd, 7th paragraph: I did it contradicting that its phrased that “Although the disadvantage of simulating in silico data is obvious (it is not ‘real’), there are some substantial advantages: it is a lot cheaper than performing sequencing runs, a lot faster, and can be applied to any genome previously sequenced.” and “However, a major drawback is that simulating variation the way nature evolves is very challenging – genetic variation happens in places in the genome where it is hardest to find.” And “although this requires strict annotation of the experiment; c) it will not be possible (besides rare exceptions) to build datasets for the different platforms using the same initial samples.” First of all, its not all that can prepare simulated datasets and secondly, its correct that it will never mimic nature, Thus, I don’t see why this is so heavily recommended.

**REPLY:** We have rewritten section 3.1 to take the suggestion of the reviewer into account by rendering the second approach for generating benchmark data, i.e. sequencing of real samples on the condition that their AMR determinants are well-established by other approaches (such as conventional PCR and/or Sanger sequencing), more prominent.

- Page 9 1st paragraph: I miss N50, no of contigs etc.. to be mentioned as QC metrics.

**REPLY:** We have now included quality of the assembly as an example of an important QC metric.

- Page 9 2nd paragraph: Not easy to understand.

**REPLY:** This paragraph has been rewritten for clarity.

- Page 9 2.4 1st paragraph: “a very pragmatic approach could be the generation of random DNA sequences, to which particular sequences of interest are added (i.e. fragments of AMR genes). However, there is sufficient evidence that the genomic background of the bacteria (i.e. the “non-AMR related” sequences) can have a profound influence on the performance of the pipelines”. Contradiction – see Page 7 1st, 2nd, 7th paragraph.

**REPLY:** Thanks for spotting this contradiction. It has been clarified by rephrasing.

- page 9 6th paragraph: define “phenotypic endpoint”.

**REPLY:** This has been defined in the first paragraph of section 2.5

- Page 9 6th paragraph: “Studies that evaluated AMR genotype to phenotype relationships have indicated that despite generally high correspondence, this can vary greatly between pathogens / case studies, and even for different antimicrobial agents within the same species 57,58.” I need to be further elaborated – what do one trust the phenotypic data or detected genes.

**REPLY:** The subsequent paragraphs explain that focusing on a genomic endpoint has advantages. The name of the section has been change, as its aim is not to assess what is better between the two described endpoints.

- Page 9 intro to bullets: define “genomic endpoint”.

**REPLY:** This has been defined in the first paragraph of section 2.5

- Page 9 section 2.6: Agree that metadata is needed but it needs to be explained that
its not needed for the benchmarking itself but for others to use the dataset for future exercises.

**REPLY:** Added a sentence to clarify this.

- Page 10 1st paragraph of section 3.1: explain what is meant by “agreed minimum standards”- what performance metrics.
  
  **REPLY:** We have substantially revised section 3.1 to render the “agreed minimum standards” clearer.

- Page 10 3rd paragraph of section 3.1: I find it contradicting to Page 7 1st, 2nd, 7th paragraph.
  
  **REPLY:** changed according to request.

- Page 10: WHO CIA has been updated – provide ref.
  
  **REPLY:** the WHO web page states the a new update will be issued in 2022. WHO release: 2020 annual review of the clinical and preclinical antibacterial pipelines evaluates the potential of antibacterial candidates (https://www.who.int/publications/i/item/9789240021303)

- Page 10: The decision has been updated in 2021 – provide ref.
  
  **REPLY:** changed according to request.

- Page 13: Tabel 3 greatly lack a million PT/ EQA reports from EURLs e.g.
  

  **REPLY:** We agree that a lot of PT/ EQA reports from EURLs exist. However, Table 3 is proposed as “a non-exhaustive list of recent references to be used as a starting point” and, among them, reference 85 is a report from the EURL-AR. Anyway, we modified the text to highlight the relevance of these reports.

Page 14 section 3.3: I would omit this part as it add more confusion to bring in also metagenomics to the concept – a completely different approach with complex samples. Past studies has also show that benchmarking metagenomics is not a trivial discipline.

**REPLY:** We did not omit this part as we believe it is linked to the resistome concept that we addressed, thanks to your suggestions.

**Competing Interests:** No competing interests were disclosed.
The benefits of publishing with F1000Research:

- Your article is published within days, with no editorial bias
- You can publish traditional articles, null/negative results, case reports, data notes and more
- The peer review process is transparent and collaborative
- Your article is indexed in PubMed after passing peer review
- Dedicated customer support at every stage

For pre-submission enquiries, contact research@f1000.com